
AI-generated image.
The short answer: the active and its percentage decide the procedure
To sell a product in Korea with a skin-brightening or anti-wrinkle claim, the product has to be a functional cosmetic, and before it is sold it must either pass a review or be covered by a filed report. Which of the two applies is mostly decided by which active ingredient you use and at what concentration. An active that appears in the MFDS notice, used at the listed concentration, removes most of the data burden. An active outside the list, or a different concentration, means a review supported by safety and efficacy data.
That is why this decision belongs in the brief, not at the end of formulation. This article sets out what a brand planning a serum or cream should settle before contacting a manufacturer.
1. "Brightening" and "anti-wrinkle" are functions defined by law
Article 2(2) of the Korean Cosmetics Act (Act No. 22113, in force 20 October 2026) defines functional cosmetics and names, among others, products that help brighten (whiten) the skin and products that help improve skin wrinkles. Article 2 of the Enforcement Rule (Prime Ministerial Decree No. 2109, in force 2 April 2026) describes the scope more precisely:
- helping to brighten the skin by preventing melanin deposition and so suppressing the formation of spots and freckles (item 1)
- helping to brighten the skin by lightening the colour of melanin already deposited (item 2)
- relieving or improving skin wrinkles by giving the skin elasticity (item 3)
A cosmetics manufacturer, a responsible seller of cosmetics, or a university or research institute that wants a product recognised and sold with one of these functions must, for each product, either obtain a review or file a report, and the same applies when a reviewed item or a filed report is changed (Act, Article 4(1)). A functional cosmetic that has neither been reviewed nor reported may not be sold, or manufactured, imported, stored or displayed for sale (Act, Article 15, item 1).
2. Two routes: report and review
A report means filing a "Report on Functional Cosmetics Excluded from Review" with the head of the National Institute of Food and Drug Safety Evaluation (Enforcement Rule, Article 10(2)). Article 10(1) of the Enforcement Rule defines which products qualify. This article looks at two of its categories (item 3, on products that combine sunscreen actives with these actives, is not covered here).
- Products identical to a notified item (item 1). The type and content of the active ingredient, the efficacy statement, the directions and dosage, and the specifications and test methods are the same as those of an item notified by the MFDS. All four have to match.
- Products identical to one already reviewed (item 2). The type, specification and content of the active raw material, the efficacy statement, the specifications (other than the pH specification) and test methods, the directions and dosage, and the dosage form are all the same. Solutions, lotions and creams are treated as the same dosage form. Two conditions are attached. Either the responsible seller is the same, or the manufacturer that designed, developed and produced the product is the same, and for brightening and anti-wrinkle products the earlier reviewed item must be one whose efficacy was demonstrated in a comparison against a control without the active ingredient.
A review covers everything else. For each product, the applicant submits a review request with the following data (Enforcement Rule, Article 9(1)):
- data on origin and development history
- safety data (single-dose toxicity, primary skin irritation, eye mucosa irritation, skin sensitisation, phototoxicity and photosensitisation, human patch test)
- efficacy or function data (efficacy test, human application test)
- data on specifications and test methods, including a sample
The proviso to the same paragraph states that for items whose ingredient and content have been notified, the first groups of data may be omitted, and for items whose specifications and test methods have been notified, the specifications and test methods data may be omitted. In other words, "is it a notified active?" and "do the specifications and test methods also match the notice?" are two separate questions, and each needs its own answer.
3. The actives and concentrations in the notice
Annex 4 of the MFDS notice Regulation on the Review of Functional Cosmetics, titled "Types of functional cosmetics for which data submission is omitted", lists the ingredients and contents below. Article 6(3) of the notice exempts items whose ingredient and content are listed in Annex 4 from submitting origin and development, safety and efficacy data. The ingredient names are English renderings of the Korean names used in the notice.
Scroll horizontally to see all columns when the table is wider than your screen.
| Function | Ingredient | Content |
|---|---|---|
| Brightening | Paper mulberry extract | 2% |
| Brightening | Arbutin | 2 to 5% |
| Brightening | Ethyl ascorbyl ether | 1 to 2% |
| Brightening | Oil-soluble licorice extract | 0.05% |
| Brightening | Ascorbyl glucoside | 2% |
| Brightening | Magnesium ascorbyl phosphate | 3% |
| Brightening | Niacinamide | 2 to 5% |
| Brightening | Alpha-bisabolol | 0.5% |
| Brightening | Ascorbyl tetraisopalmitate | 2% |
| Anti-wrinkle | Retinol | 2,500 IU/g |
| Anti-wrinkle | Retinyl palmitate | 10,000 IU/g |
| Anti-wrinkle | Adenosine | 0.04% |
| Anti-wrinkle | Polyethoxylated retinamide | 0.05 to 0.2% |
Three conditions have to be read together with the table. All three are written in Annex 4.
- The dosage forms are fixed. Lotions, solutions, creams, solid forms and soaked sheet masks only.
- The efficacy wording is fixed. "Helps brighten the skin" or "Helps improve skin wrinkles", as the Korean statutory phrases translate.
- The directions are fixed. Take an appropriate amount and spread it evenly over the skin; for a soaked mask, apply it, remove the sheet after 10 to 20 minutes and spread the remaining product evenly.
The content above was checked in the version published on the Korea Law Information Center as MFDS Notice No. 2026-75 (partially amended 10 November 2026, in force 11 November 2027). The stated reasons for that amendment describe it as concerning the data requirements and exemptions for sunscreen products. Notices are amended from time to time, so the version in force when you lock the product should be confirmed again with your manufacturer.
4. One "niacinamide serum", different routes depending on the brief
Scroll horizontally to see all columns when the table is wider than your screen.
| What the brief says | What to confirm |
|---|---|
| A notified active at the notified content, in a listed dosage form with the fixed wording | Whether the specifications and test methods also match the notified item, so that the report route applies |
| A notified active, but outside the listed content | Whether a review is required, and who prepares which data |
| A brightening or anti-wrinkle claim based on an active not on the list | A review with safety and efficacy data, and its timeline |
| A formula the manufacturer has already had reviewed, used unchanged | Whether the manufacturer that designed, developed and produced it is the same, and whether the earlier item proved efficacy against a control |
| A general cosmetic with no brightening or anti-wrinkle claim | Whether any wording on the label or in advertising could be taken as a functional claim |
The last row is also a real option. Including an ingredient and claiming its function are different things, so a product can be launched as a general cosmetic without functional wording. However, labelling or advertising that may cause a non-functional cosmetic to be mistaken for a functional cosmetic is prohibited (Act, Article 13(1)), so the wording you want to use has to be decided first. How wording relates to substantiation is covered in advertising claims and substantiation.
Where a brand wants to combine a brightening active and an anti-wrinkle active in one product and make both claims, this article does not state which procedure applies. That is a product-by-product determination, so confirm it through your manufacturer.
5. Who files, and what changes
- Who files. The Act names the cosmetics manufacturer, the responsible seller, and universities or research institutes as the parties (Act, Article 4(1)). Decide before the contract whether your brand is the responsible seller or whether the manufacturer files. The duties that stay with the brand are set out in what the brand owner still has to do.
- Base formula or new formula. Using a formula the manufacturer has already had reviewed can open the report route under its own conditions (section 2 above). Changing the formula can take the product outside those conditions. The difference between the two paths is explained in base formula vs custom formulation.
- Changes. Changing a reviewed item or a filed report requires the same procedure (Act, Article 4(1), second sentence). If you plan to change the active content or the dosage form after launch, say so at the start.
- Export-only products. The procedure above applies to products sold in Korea as functional cosmetics. How the same wording is classified in the destination market depends on that country's rules. The reach of Korean law is covered in export-only cosmetics.
The same structure applies to other functions. Sun protection is covered in developing sunscreen, and hair-loss relief in private label shampoo.
6. What to write in your first inquiry
- The function you want to claim: brightening, anti-wrinkle, both, or no functional wording.
- The active and content you want: state it if you have decided, or write "propose within the notified actives".
- The dosage form: solution (serum or toner), lotion, cream, soaked sheet mask and so on.
- The markets: sale in Korea, export only, or both.
- Your plan for who files: whether your brand is registered as a responsible seller.
- The wording you want on the pack and in advertising: write the exact phrases.
With these six lines, the procedure, the data and the formula can be reviewed together. You can start with a formulation development consultation, and the remaining fields of a brief are covered in writing a product brief. Quantities, unit prices and schedules depend on the product and its conditions and are confirmed in consultation.
Frequently asked questions
Does adding niacinamide automatically make a product a brightening functional cosmetic?
No. To be recognised and sold as a functional cosmetic, each product has to be reviewed or reported (Act, Article 4(1)). The presence of the ingredient alone does not complete that procedure.
What happens if a notified active is used above the notified content?
The content then differs from what Annex 4 lists, so the data exemption tied to that table cannot be assumed to apply as it stands. Which procedure and which data are required should be confirmed with the manufacturer before the formula is locked.
If the manufacturer's formula has already passed a functional review, does our brand's product only need a report?
It can, if the conditions are met. Article 10(1), item 2 of the Enforcement Rule makes a product reportable when the manufacturer that designed, developed and produced it is the same, or the responsible seller is the same, and the type, specification and content of the active raw material, the efficacy statement, the specifications and test methods, the directions and dosage, and the dosage form are all the same. For brightening and anti-wrinkle products, the earlier reviewed item must be one whose efficacy was demonstrated against a control.
Sources
- Cosmetics Act of Korea, Articles 2(2), 4, 13(1) and 15, Act No. 22113, in force 2026-10-20 (Korea Law Information Center) (accessed 2026-11-22) ↗
- Enforcement Rule of the Cosmetics Act, Articles 2, 9 and 10, Prime Ministerial Decree No. 2109, in force 2026-04-02 (Korea Law Information Center) (accessed 2026-11-22) ↗
- Regulation on the Review of Functional Cosmetics, Articles 4 and 6 and Annex 4, MFDS Notice No. 2026-75, amended 2026-11-10, in force 2027-11-11 (Korea Law Information Center) (accessed 2026-11-22) ↗